The Bayh-Dole Act of 1980 is arguably the single most consequential piece of legislation in the history of American biomedical commercialization. It transferred ownership of federally funded inventions from a sclerotic government bureaucracy to the universities and small businesses that actually created them, unlocking a wave of private investment that eventually built the modern U.S. biopharma industry. One 45-year-old provision buried inside it — the march-in right under 35 U.S.C. § 203 — has never been exercised by a single federal agency. Not once.
That record of total inaction makes what is happening right now all the more striking. The Biden administration cracked open the door to price-based march-in with a December 2023 draft NIST framework that explicitly listed drug pricing as a relevant factor. Then the Trump administration, in an entirely different political register, threatened in August 2025 to march in on Harvard University’s patent portfolio over compliance failures, demanding a full inventory of every patent stemming from federally funded research by September 5, 2025. Commerce Secretary Howard Lutnick posted the letter publicly on X with the message: ‘Taxpayers deserve the benefit of the bargain.’
This is no longer a theoretical exercise. For IP teams, portfolio managers, and institutional investors, march-in authority has moved from legal footnote to active risk factor. This guide provides the technical depth, litigation history, IP valuation implications, and investment strategy frameworks needed to operate in this new environment.
The Pre-Bayh-Dole Era: Why the Government Held 28,000 Patents Nobody Used
The Title Policy Failure
Before 1980, the default federal rule was simple and counterproductive: if a private entity used federal research funding to create an invention, the government took ownership. The resulting portfolio, approximately 28,000 patents held by various federal agencies, was a bureaucratic monument to misallocated capital. A 1978 Government Accountability Office report found that fewer than 5% of those patents had ever been licensed for commercial development. The rest sat unused. Taxpayer dollars funded the science; no one funded the delivery.
The core problem was structural. Companies would not invest the capital required to develop a raw university discovery into a marketable product if the best they could get was a non-exclusive government license. Non-exclusive licensing eliminated the competitive advantage that justified the development risk. Without exclusivity, there was no commercial logic in spending hundreds of millions on Phase II and Phase III trials for a compound a competitor could license the moment you proved it worked.
The result was a systematic failure to translate basic science into public benefit, a gap between NIH-funded discovery and commercial delivery that analysts at the time called the ‘valley of death.’ It was particularly acute in pharmaceuticals and medical devices, where development costs and timelines were longest and the need for patent-backed exclusivity was greatest.
Senators Bayh and Dole: The Bipartisan Bargain
Democrat Birch Bayh of Indiana and Republican Bob Dole of Kansas proposed a structural fix: let universities and small businesses elect title to inventions made with federal money. The logic was that institutions closer to the science were better positioned to find commercial partners than a centralized federal licensing apparatus. Give them ownership, and they have an incentive to seek licensees. Give companies the ability to secure exclusive licenses, and they have an incentive to take development risk.
The University and Small Business Patent Procedures Act of 1980, signed by President Jimmy Carter on December 12, passed with broad bipartisan support because it solved a problem that both parties agreed existed. Its downstream effects were substantial. The Bayh-Dole framework is credited with contributing an estimated $1.7 trillion in economic output to the U.S. economy, generating over four million jobs, and supporting more than 1,500 university spinout startups annually. In FY 2023, colleges and universities spent approximately $109 billion on R&D, of which $59.6 billion — 55% — came from federal sources, according to the Congressional Research Service. That entire ecosystem rests on the IP ownership structure Bayh-Dole created.
Section 203: The Safety Valve
The Act’s architects understood that granting private control over taxpayer-funded inventions required a safeguard. Section 203 — the march-in provision — is that safeguard. It authorizes the federal funding agency to require the patent holder to grant a license to a ‘responsible applicant’ on ‘reasonable terms’ in specific circumstances. If the patent holder refuses, the government can grant the license itself. The patent holder retains ownership; the patent’s commercial exclusivity is effectively broken.
This power is tethered to four statutory triggers defined in 35 U.S.C. § 203(a). No agency can exercise it outside these four conditions. Understanding them precisely, including the textual ambiguities each contains, is the foundation of every march-in dispute.
Key Takeaways: Bayh-Dole Origins
The pre-1980 system failed because government ownership of research IP eliminated private companies’ commercial incentive to develop it. Bayh-Dole transferred ownership to universities and small businesses, creating the public-private commercialization pipeline that underlies modern U.S. biopharma. Section 203’s march-in right was built in as a public-interest backstop. The fundamental tension in the law — maximum private incentive for commercialization versus the public’s right to benefit from its investment — was present at signing and has never been fully resolved.
The Four March-In Triggers: A Clause-by-Clause Technical Analysis
Trigger 1: Failure to Achieve ‘Practical Application’
The first and most litigated trigger: the agency determines that action is necessary because the contractor or licensee has not taken, or is not expected to take within a reasonable time, effective steps to achieve practical application of the subject invention in its field of use.
The Act defines practical application in Section 201(f) as manufacturing, practicing, or operating the invention ‘under such conditions as to establish that the invention is being utilized and that its benefits are available to the public on reasonable terms.’
The operative phrase — ‘available to the public on reasonable terms’ — is the source of the entire drug pricing controversy. Two distinct legal interpretations have hardened over four decades of debate.
The first interpretation, advanced by patient advocates and progressive lawmakers, holds that a drug priced at levels that make it inaccessible to the patients who need it cannot logically be considered available on ‘reasonable terms.’ Under this reading, an annual treatment cost of $193,000 for Xtandi in the U.S. compared to $24,000 in Japan, where manufacturer Astellas is headquartered, fails the ‘reasonable terms’ standard on its face.
The second interpretation, consistently adopted by the NIH across multiple administrations, holds that ‘reasonable terms’ refers to commercial availability and contractual licensing terms, not price. The NIH has argued that Congress had multiple opportunities to insert explicit price control language into Bayh-Dole and declined to do so, and that ‘reasonable terms’ cannot be retroactively reinterpreted to mean what Congress chose not to write.
Former NIH Director Francis Collins stated the agency’s position bluntly: march-in applies only ‘where a drug is simply not available to the public under any circumstance.’ That position held for over two decades — until the December 2023 draft NIST framework challenged it directly by listing price as a factor in practical application assessments.
Trigger 2: Alleviating Health or Safety Needs
The second trigger permits march-in when action is necessary to alleviate health or safety needs that are not reasonably satisfied by the contractor, assignee, or licensees. This is the most intuitive trigger. A pandemic, a bioterrorism event, a manufacturing collapse — situations where the product exists but supply is catastrophically inadequate — are its natural domain.
The Fabrazyme case of 2010 is the most detailed test of this trigger on record. Genzyme (now Sanofi Genzyme), manufacturer of agalsidase beta (Fabrazyme), experienced severe viral contamination at its Allston, Massachusetts manufacturing facility beginning in mid-2009. The resulting shortage forced doctors to ration the Fabry disease treatment, cutting typical doses by two-thirds. Patients filed a petition asking the NIH to march in and license Shire, which produced a similar enzyme replacement therapy (agalsidase alfa, sold as Replagal) under the same product category, to increase U.S. supply.
The NIH denied the petition in 2010 for a specific and pragmatic reason: it determined that the march-in process itself — the notification, negotiation, fact-finding, and appeals mechanism laid out in the statute — would take longer to complete than Genzyme’s own remediation timeline. Marching in would not have accelerated patient access. The denial illustrated an important structural limitation: the march-in procedure is administratively slow, a point the NIH would later use explicitly when rejecting price-based Xtandi petitions on procedural grounds.
The NIST 2023 draft framework attempted to expand this trigger’s scope by suggesting that a high price could itself constitute a ‘health need not reasonably satisfied’ if it prevents patients from accessing the medicine. This interpretation would link the pricing argument to a second statutory basis, not just the ‘practical application’ trigger.
Trigger 3: Public Use Requirements Not Met
The third trigger is narrow and requires a specific pre-existing federal regulation mandating a particular public use of the invention. If a licensee is in breach of that regulation, the agency may march in. This trigger has generated the least litigation because it requires a second, independent layer of regulatory mandate before it can activate. Without a specific federal rule creating the public use obligation, there is nothing to breach.
The closest this trigger has come to practical relevance involves Department of Defense grants and medical countermeasures. The 2017 National Defense Authorization Act included report language directing the DoD to consider exercising march-in rights on drugs or vaccines resulting from DoD funding where the U.S. price exceeded the median price charged in a reference basket of comparable nations. This did not become operative policy, but it established a congressional appetite for geographically indexed price comparisons as a public-use standard — a framework that would resurface in subsequent policy proposals.
Trigger 4: Breach of U.S. Manufacturing Requirement
Section 204 of Bayh-Dole requires that any exclusive license covering a subject invention in the United States must include a clause ensuring the licensed product is ‘substantially manufactured in the United States.’ The fourth march-in trigger activates when this clause has not been obtained or when the licensee has breached it.
In practice, this trigger has been defanged by the waiver mechanism built into Section 204. Funding agencies may waive the domestic manufacturing requirement when a grantee demonstrates that reasonable efforts to license to a U.S. manufacturer have failed or that domestic manufacturing is not commercially feasible. Knowledge Ecology International’s analysis found that the NIH granted approximately 98% of such waiver requests filed between 1995 and 2020, making the provision a de facto formality in most commercial pharmaceutical contexts.
The Trump administration’s 2025 Harvard investigation changed the weight of this trigger. Commerce Secretary Lutnick’s letter cited the domestic manufacturing obligation explicitly, asking Harvard to document whether licenses on each federally funded patent mandated substantial U.S. manufacturing. Analysts read this as the administration testing the fourth trigger as a lever for manufacturing reshoring policy — a goal entirely distinct from the price-access debate that consumed the Biden era’s march-in discussions.
Key Takeaways: The Four Triggers
Trigger 1 (‘practical application’) is the most contested. The phrase ‘available on reasonable terms’ is where the pricing debate lives, and no court has ever authoritatively interpreted it. Trigger 2 (‘health or safety needs’) is the most intuitive but proved difficult to activate in the Fabrazyme case because of the march-in procedure’s inherent slowness. Trigger 3 is narrow and requires a pre-existing federal regulation creating the public use obligation. Trigger 4, long treated as a compliance formality with near-universal waivers, may now carry new strategic weight under a reshoring-focused executive branch.
The Complete Litigation and Petition History: 45 Years of Denials
CellPro (1997): Establishing the Competitive-Dispute Bar
The first march-in petition arose not from patient advocacy but from patent litigation. CellPro held an exclusive license from Johns Hopkins University to technology for stem cell separation. Competing firm Baxter Healthcare alleged patent infringement and, along with co-petitioners, asked the NIH to march in and grant Baxter a license, arguing CellPro was failing to make the technology broadly available.
NIH Director Harold Varmus denied the petition in 1997 in a letter that established a precedent the agency has cited in every subsequent denial: march-in rights are not a mechanism to adjudicate patent infringement disputes or punish a licensee for business practices that a competitor dislikes. The relevant question, Varmus stated, is whether the licensee is taking effective steps to bring the invention to the public. CellPro was commercializing the technology. There were no grounds to march in.
This 1997 precedent closed one potential avenue for march-in misuse — weaponizing the provision as a competitive tool in patent litigation — while leaving the pricing question entirely unresolved.
Norvir (Ritonavir) (2004): The Pricing Debate Ignites
Abbott Laboratories (now AbbVie) developed ritonavir with NIH funding as a standalone HIV antiretroviral. By 2003, ritonavir’s primary commercial use had shifted: it was being used at sub-therapeutic doses as a pharmacokinetic booster — a ‘pharma-enhancer’ — that increased the plasma concentrations of co-administered HIV protease inhibitors, extending their effectiveness. Recognizing this, Abbott raised Norvir’s price by 400% in 2003, from $1.71 to $8.57 per day.
The price increase was openly strategic. Abbott’s own combination HIV pill, Kaletra (lopinavir/ritonavir), already incorporated ritonavir at the boosting dose. By making standalone ritonavir dramatically more expensive, Abbott made it costlier for competing manufacturers to build ritonavir-boosted regimens, creating a structural pricing moat around Kaletra. AIDS activists and HIV patients filed a march-in petition with the NIH arguing the price increase meant Norvir was no longer available on ‘reasonable terms.’
The NIH’s 2004 denial became the definitive policy statement on pricing for the next two decades. The agency stated explicitly: ‘Because the legislative history of the Bayh-Dole Act is silent on the issue of product pricing and because the NIH finds no other compelling justification for the use of this extraordinary remedy, the NIH concludes that… a march-in proceeding is not warranted.’ This reasoning — legislative silence on pricing, extraordinary remedy standard — became the template for every subsequent pricing-based denial.
Fabrazyme (Agalsidase Beta) (2010): The Supply Failure Case
As detailed in the Trigger 2 analysis above, the Fabrazyme petition in 2010 was the only major case to invoke the health and safety trigger rather than the pricing argument. The NIH’s denial was pragmatic rather than doctrinal. It did not hold that supply shortages can never trigger march-in, only that in this specific case the remedy would arrive too slowly to help. The case confirmed the procedural limitation as a real-world constraint: the statutory march-in process, with its mandatory notification, consultation, fact-finding, and appeal stages, is poorly designed for emergency response.
Xtandi (Enzalutamide): The Definitive Case Study
No drug has accumulated more march-in litigation history than enzalutamide, and the volume of that history is directly proportional to the economic stakes.
IP Valuation: The Xtandi Patent Estate
Enzalutamide’s core patent, U.S. Patent 7,709,517, covers the compound itself and arose from research at UCLA funded by NIH grants and U.S. Army Medical Research grants. UCLA licensed the technology in 2005 to Medivation Inc. Pfizer acquired Medivation for $14 billion in 2016, with Xtandi as the primary strategic asset. Astellas separately holds commercialization rights outside North America and manufactures the product globally under a 2009 collaboration agreement with Medivation (now Pfizer).
As of 2025, DrugPatentWatch data show six patents actively protecting Xtandi’s U.S. market position across the NDA listings, with 191 patent family members in 35 countries and nine active Paragraph IV challenges from generic manufacturers. Three tentative ANDA approvals are already on record. The compound patent for the U.S. market expires in 2027, with a European cliff arriving in 2026. GlobalData projects peak Xtandi revenues of approximately $5.59 billion in 2025, declining to $2.24 billion by 2030 as generic entry erodes exclusivity. The 2023 Medicare Part D spend on enzalutamide alone was $2.6 billion — a single drug consuming the equivalent of approximately 5.5% of the NIH’s annual research budget in government reimbursement outlays.
The price gap motivating all march-in petitions is stark: Drugs.com cited a 2023 coupon price of approximately $15,922 for a 120-capsule pack of Xtandi (40 mg), equivalent to $132.68 per capsule. At the standard 160 mg daily dose (four capsules), the annual U.S. treatment cost approaches $193,000. In Australia, the same product cost approximately AUD $3,313 for 112 capsules in 2025, roughly USD $18.94 per capsule, according to Knowledge Ecology International — approximately one-seventh the U.S. coupon price. In Japan, where Astellas is headquartered, the price has historically ranged from $20 to $35 per capsule. U.S. prices have increased more than 75% since Xtandi’s 2012 launch while Japanese prices have declined.
Petition History
The first formal march-in petition on Xtandi was filed in 2016 by Knowledge Ecology International (KEI) and associated patient advocates. The NIH denied it, reiterating the Norvir standard: price alone is not grounds for march-in.
A second petition followed in 2021. In 2022, Senators Bernie Sanders (I-VT), Ron Wyden (D-OR), and Peter Welch (D-VT) wrote directly to HHS Secretary Xavier Becerra urging action. The NIH denied the petition again in March 2023, this time adding a new and specifically procedural rationale: given the drug’s remaining patent life and the ‘lengthy administrative process involved for a march-in proceeding,’ march-in would not be an effective mechanism for lowering price even if it were otherwise appropriate. The comment acknowledged the impending 2027 patent cliff would bring generic entry without government action.
In April 2024, three nonprofit organizations — KEI, Universities Allied for Essential Medicines (UAEM), and Universities Allied for Critical Treatments (UACT) — filed a new type of request, not a march-in petition but a request for CMS to use its own government license rights under 35 U.S.C. § 202(c)(4) and 28 U.S.C. § 1498 to authorize generic manufacturing for Medicare programs. Costplusdrugs.com reportedly offered to distribute such a generic. HHS Chief Competition Officer Stacy Sanders declined action in August 2024.
The Xtandi case demonstrates a recurring pattern: advocates test multiple statutory pathways — march-in under Section 203, government license under Section 202(c)(4), and compulsory government use under 28 U.S.C. § 1498 — as the primary route remains blocked. Each successive denial pushed the legal argument in a slightly different direction without generating a successful outcome for petitioners.
Harvard University (2025): The New Political Register
The August 2025 Commerce Department action against Harvard represents a qualitatively different kind of march-in threat. This was not a patient advocacy petition filed by a nonprofit. It was the executive branch of the U.S. government, through the Secretary of Commerce, initiating a formal compliance review against one of the country’s most IP-rich universities.
Commerce Secretary Lutnick’s letter to Harvard President Alan Garber on August 8, 2025, accused Harvard of three Bayh-Dole violations: failure to make timely disclosures of federally funded inventions, failure to ensure substantial U.S. manufacturing for licensed technologies, and failure to maximize public benefit. Harvard was given until September 5, 2025 to provide a comprehensive patent inventory plus documentation proving compliance. Harvard held more than 58,000 patents as of July 1, 2024, and maintains over 900 active technology licenses generating revenues that fund its research enterprise. The patents potentially at risk are valued in the hundreds of millions of dollars.
Legal analysts widely characterized the action as carrying political motivations — the Trump administration had already frozen all federal funding to Harvard in April 2025 and was facing a lawsuit from the university over that freeze. But the legal mechanism invoked was real. The Bayh-Dole compliance violations cited, particularly the U.S. manufacturing obligation and disclosure timing requirements, fall squarely within the statute’s actual text. The Bayh-Dole Coalition cautioned that ‘casting doubt on the security of university patents, even for a single institution, injects uncertainty into the market, discourages investment, and punishes the entrepreneurs who take risks needed to bring innovations to life.’
For pharma and biotech IP teams, the Harvard case carries a specific warning independent of its politics: the Trump administration has demonstrated a willingness to use the march-in compliance framework as a pressure tool against institutions with whom it has policy disputes. A company whose key drug IP traces to a university that has drawn government scrutiny for other reasons faces compounded Bayh-Dole risk.
Key Takeaways: Petition History
Every march-in petition since 1980 has been denied. The government has never granted a single petition in 45 years across multiple administrations. The NIH’s consistent rationale — legislative silence on price, extraordinary remedy standard, procedural inefficiency — has been stable across Republican and Democratic administrations until 2023. The Harvard 2025 action signals that march-in can now be weaponized for compliance enforcement against institutions in political conflict with the administration, introducing a new and structurally distinct risk category beyond patient advocacy petitions.
The Core Legal Dispute: Can Price Satisfy the ‘Reasonable Terms’ Standard?
The Textual Argument for Price-Based March-In
The case for treating unaffordable pricing as a failure of ‘practical application’ rests on statutory text and logical inference. If ‘benefits… available to the public on reasonable terms’ is to mean anything, it must incorporate accessibility. A product stocked in every pharmacy in the country but priced at $193,000 per year is functionally inaccessible to the majority of patients who lack comprehensive insurance coverage or manufacturer patient assistance program eligibility. The 2023 Medicare Part D data on Xtandi — $2.6 billion in government outlays for a single compound — demonstrates that even insured patients with government coverage are generating massive public cost through what advocates characterize as unreasonable pricing.
Advocates also point to a structural argument in Bayh-Dole’s legislative history. The original draft of the Act included a ‘recoupment’ provision that would have required licensees to pay back some portion of the federal research investment. That provision was removed in favor of march-in rights, which some scholars interpret as evidence that march-in was intended to be the mechanism for protecting the public’s financial interest in taxpayer-funded IP.
The 2002 Washington Post op-ed by Senators Bayh and Dole, frequently cited by industry to argue that the Act was ‘not intended’ as a price control tool, is more ambiguous on close reading. The senators wrote that Bayh-Dole ‘did not intend that government set prices on resulting products.’ But they also wrote that march-in is available if a company ‘has not taken steps to commercialize the invention or is not making it available to the public’ — a clause advocates argue encompasses availability at an accessible price.
The Structural Argument Against Price-Based March-In
The pharmaceutical industry’s argument is not merely textual. It is a predictive model of how investors and companies would modify behavior in response to price-based march-in risk.
The biotech-pharma R&D model is built around a specific return profile. According to Tufts Center for Drug Development estimates, the fully capitalized cost of developing a new prescription medicine, including the cost of failed candidates that are necessary to fund alongside the winner, is approximately $2.6 billion per approved drug. Phase III trials alone for an oncology asset routinely cost $200 million to $500 million. The company or investor bearing those costs requires a predictable period of exclusivity to generate a return before generic entry. That is the deal Bayh-Dole created.
If the government can declare a price ‘unreasonable’ after the development has been completed and the drug approved, it retroactively changes the deal. The result would not be abstract: venture capital firms that fund early-stage biotech spun out of university labs price their investments based on expected terminal value, which incorporates projected peak revenues. An executive action making those revenues vulnerable to government price intervention would reprice every Bayh-Dole-encumbered asset downward. The VC response — redirecting capital away from federally funded university spinouts toward private research institutions with no Bayh-Dole strings — is predictable and would harm the universities the Act was designed to empower.
The Biotechnology Innovation Organization (BIO) made this argument explicitly in its 2023 comments on the NIST draft framework, warning that uncertainty about government price intervention ‘would dismantle the very public-private partnerships that Bayh-Dole was designed to create.’ The Association of University Technology Managers (AUTM) echoed it from the university side, citing the $1.7 trillion in economic output and 4 million jobs generated by the Bayh-Dole ecosystem.
There is also a practical implementation problem that neither side has solved: who sets the ‘reasonable’ price, using what methodology? Manufacturing cost? R&D amortization? Value-based pricing benchmarks? International reference pricing using which country basket? The NIH is a scientific and grant-making institution with no statutory pricing authority, no economic modeling mandate, and no enforcement mechanism for a price ruling. Creating one by executive interpretation would require regulatory infrastructure that does not exist.
The Competing Historical Record
The Trump administration’s first term added a data point that complicates the partisan framing of the march-in debate. In January 2021, NIST under the Trump administration published a proposed rule that would have explicitly prohibited march-in ‘on the sole basis of product pricing.’ This was a formal regulatory move to close the door the Biden administration would later attempt to reopen.
President Biden issued Executive Order 14036 directing NIST not to finalize that price-protection clause. The March 2023 final Bayh-Dole rule omitted it. By December 2023, the draft NIST interagency framework explicitly re-inserted price as a relevant consideration. The comment period drew 51,873 public comments through the Federal Register — a volume that itself indicates the political intensity of the dispute.
Then, on October 1, 2025, a materially significant regulatory event occurred that crossed party lines: the Biden administration’s ‘affordability’ mandate in NIH-owned patent licenses, implemented in early 2025, was formally adopted by the Trump administration. This suggests that some form of pricing accountability for NIH-licensed patents has achieved a durable, bipartisan institutional foothold — even as the broader march-in framework remains contested.
Investment Strategy: Pricing Risk in Federally Funded Drug Assets
Portfolio managers and institutional investors evaluating biopharma assets with Bayh-Dole exposure should now treat march-in risk as a discrete, quantifiable component of IP valuation, rather than a legal footnote.
For assets currently on the market, the practical march-in risk is modulated by three factors: remaining patent life, administrative process duration, and the existence of viable price-reducing alternatives (IRA negotiation eligibility, Paragraph IV challenge pipeline, imminent generic entry). Xtandi illustrates this clearly — the NIH’s 2023 denial specifically noted that given the 2027 patent cliff, a march-in proceeding would not be a faster path to price reduction than simply waiting for generic entry. For assets with long remaining exclusivity windows (10+ years), with high U.S.-international price differentials, and with clear NIH or DoD funding provenance, march-in risk carries material NPV implications.
For assets in development, Bayh-Dole encumbrance should trigger three specific actions in due diligence: confirmation of the federally funded invention disclosure history in the target’s patent chain; assessment of the price sensitivity of the eventual commercial market (low-volume rare disease products with extreme pricing are more exposed than moderate-volume drugs in competitive therapeutic areas); and a review of whether the development licensee has any pending Bayh-Dole compliance issues, particularly around timely invention disclosure and domestic manufacturing. The Harvard case established that compliance failures on these procedural requirements create a separate avenue for government action independent of any pricing argument.
Bayh-Dole’s IP Valuation Mechanics: A Technical Framework for Analysts
What ‘Government Interest’ Statements Mean for Patent Valuation
Every patent arising from federally funded research must contain a Statement of Federally Sponsored Research, disclosing the government’s rights. This statement, typically appearing on page one of the patent document, is the primary signal that the asset is subject to Bayh-Dole march-in authority. But the chain can extend multiple steps from the patent holder. A large pharmaceutical company may hold a patent it licensed from a university spinout that was itself funded by a NIH Small Business Innovation Research (SBIR) grant. The originating federal funding makes the patent subject to Bayh-Dole regardless of how many commercial transactions have intervened since the original grant.
This chain analysis is a specific due diligence task distinct from standard freedom-to-operate (FTO) searches. FTO analysis determines whether a product infringes third-party patents. Bayh-Dole chain analysis determines whether the company’s own patents are encumbered by government march-in authority. The two are methodologically different and require different data sources.
Specialized pharma intelligence platforms like DrugPatentWatch provide the patent-level data — NDA-to-patent cross-references, patent family memberships, expiration dates, and Paragraph IV certification histories — that forms the foundation of this analysis. Identifying the Bayh-Dole Statement of Federally Sponsored Research within those patent records, and tracing the original funding agency, is the next step. For large portfolio reviews (M&A targets, licensing negotiations, or internal compliance audits), this process benefits from systematic screening rather than document-by-document review.
The Royalty Stack: What a March-In Actually Does to Revenue
A granted march-in petition does not confiscate the original patent. The patent holder retains ownership and continues to receive royalties from the new compulsory licensee. The economic destruction of a march-in comes from the elimination of exclusivity, not from the loss of the underlying IP asset. The original licensee moves from a monopoly pricing position to a competitive one, where the ‘reasonable royalty’ standard applied in a compulsory licensing scenario will be materially below what the market was delivering under exclusivity.
For a drug like Xtandi, with a 2025 U.S. annual revenue run rate of approximately $5.6 billion, the elimination of exclusivity through march-in would replicate the economic effect of a patent cliff — a rapid decline to generic commodity pricing. Research on U.S. generic drug markets shows prices typically fall to 10%-30% of branded levels within two years of multi-source generic entry. For Pfizer and Astellas, this scenario was approaching anyway via the 2027 patent expiration and the existing pipeline of three tentative ANDA approvals. The march-in threat on Xtandi is declining in practical significance precisely because biological patent expiry and generic entry will deliver the same price outcome without government action.
The more relevant march-in risk for forward-looking investors lies in recently approved drugs with long remaining exclusivity windows, where the same Bayh-Dole funding provenance creates a threat that cannot be timed away.
The ‘Patent Thicket’ Defense and Its Bayh-Dole Limitations
Pharmaceutical companies commonly protect key drugs with overlapping ‘patent thickets’ — large portfolios of patents covering the base compound, formulations, polymorphs, manufacturing processes, delivery systems, metabolites, and method-of-use claims. A single FDA-approved drug may be covered by dozens of patents with staggered expiration dates, creating an evergreening effect that extends effective market exclusivity well beyond the compound patent’s nominal expiration.
Against a Paragraph IV challenge from a generic manufacturer, a patent thicket is a proven defensive weapon. Against Bayh-Dole march-in, its effectiveness is more limited. March-in authority attaches to the specific ‘subject invention’ — the patent or patents created with federal funds — and does not automatically extend to non-federally funded patents in the same product’s thicket. However, if the federally funded patent is a composition-of-matter patent covering the base compound, it is typically the one whose breach of exclusivity actually enables generic competition. Secondary patents covering formulations or methods of use may survive a march-in on the base compound, but their commercial value evaporates once the compound itself is available under a compulsory license.
For the government to exercise march-in, petitioners need to establish that the specific federally funded patent is a ‘necessary’ component of the product — that without it, the product could not be made or sold. If a company has successfully built a thicket where the federally funded patent covers only a minor, design-aroundable aspect of the product, march-in risk is substantially reduced. This consideration should inform both the defensive IP strategy of companies developing federally funded assets and the due diligence process of investors evaluating them.
Key Takeaways: IP Valuation and March-In
Bayh-Dole chain analysis is a distinct due diligence task from FTO. It should be standard practice in any M&A or licensing transaction involving drug assets with university research heritage. March-in eliminates exclusivity but not patent ownership; the economic damage approximates a patent cliff. Patent thickets partially mitigate this, but only when the federally funded patent is not the composition-of-matter compound patent. For assets with long remaining exclusivity and high U.S.-international price differentials, march-in risk should carry a specific discount in NPV modeling.
The NIST 2023 Draft Framework: A Clause-by-Clause Analysis
What the Framework Actually Says
The December 8, 2023 NIST ‘Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights’ drew 51,873 public comments and generated more immediate industry response than any Bayh-Dole-related action since the Act’s passage. Its significance lies less in what it mandates — it is guidance, not a binding rule — and more in what its publication reveals about the executive branch’s policy direction.
The framework structures the march-in decision around three overarching questions: Does Bayh-Dole apply to the invention? Is one of the four statutory criteria met? Would exercise of march-in support Bayh-Dole’s policy objectives?
The key innovation is in how the framework instructs agencies to evaluate Trigger 1 (practical application). It directs agencies to consider ‘whether the price or other terms at which the product is currently offered to the public are not reasonable,’ explicitly linking price to the ‘available on reasonable terms’ clause for the first time in official interagency guidance. It also suggests that agencies should evaluate the breadth of public access, not merely whether the product is commercially available to well-insured patients — a direct response to the NIH’s recurring defense that manufacturer patient assistance programs make high-priced drugs effectively accessible.
For Trigger 2 (health and safety needs), the framework suggests that a price sufficiently high to ‘burden the health care system’ or prevent patients from obtaining medically necessary treatment could itself constitute an unmet health need — connecting the pricing argument to a second statutory basis.
The framework includes eight illustrative scenarios to guide agency decision-making. Several address pharmaceutical contexts directly, including price differential between the U.S. and peer nations as a potential indicator of ‘unreasonable’ terms.
Why the Biden Administration Abandoned Finalization
The Biden administration closed the public comment period on February 6, 2024, received the responses, and then did not finalize the framework before leaving office. Several factors converged. Industry and university opposition was intense and legally coherent. The framework’s legal vulnerability — the argument that it exceeded NIST’s statutory authority under Bayh-Dole — was credibly developed in the comments by multiple law firms and academic IP scholars. Given that any agency action based on the framework would immediately face litigation, publishing final guidance that a court might strike down would have been worse than maintaining the draft posture as a threat.
The administration instead enacted what the Stites & Harbison analysis described as an ‘affordability mandate’ in licenses for NIH-owned patents in early 2025, an executive action with narrower scope but potentially more durable effect.
The Trump Administration’s Adoption
The October 1, 2025 adoption of the Biden-era NIH affordability mandate by the Trump administration is the most counterintuitive data point in recent Bayh-Dole policy. It suggests that some degree of pricing accountability for government-licensed patents is emerging as a persistent policy preference across administrations, even as the broader march-in question remains unresolved. This durability should inform long-term IP strategy for any company whose drug portfolio includes products licensed from NIH-held patents.
Global Parallels: Compulsory Licensing and the TRIPS Framework
TRIPS Article 31 and the International Standard
The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) permits member nations to grant compulsory licenses — authorizations to manufacture or use a patented product without the patent holder’s consent — under defined conditions. These include national emergencies, public non-commercial use, and remedying anti-competitive practices. The 2001 Doha Declaration on TRIPS and Public Health clarified that the agreement must be interpreted to allow compulsory licensing for public health purposes, particularly in the context of HIV/AIDS, tuberculosis, and malaria treatments.
Bayh-Dole march-in and TRIPS compulsory licensing are related but distinct instruments. TRIPS compulsory licensing is a broader power that governments can apply to any patent, regardless of how the underlying invention was funded. March-in rights are narrower, attaching only to inventions created with U.S. federal funding. A drug covered by 50 patents faces march-in risk only on the subset arising from federal grants; TRIPS compulsory licensing could in principle reach all 50.
The international experience with compulsory licensing offers a relevant behavioral model. Pharmaceutical companies facing credible compulsory licensing threats in middle-income countries — Thailand’s 2006 compulsory license for efavirenz and lopinavir/ritonavir is the canonical example — have often responded by negotiating voluntary licenses at reduced prices rather than litigating in an unfavorable local legal environment. If march-in is made credible in the U.S. through a successful first exercise, a similar pattern of preemptive voluntary price moderation could follow, which is precisely what the Biden administration appeared to be attempting through deterrence.
U.S. Competitiveness and the Capital Allocation Question
Opponents of price-based march-in consistently invoke U.S. competitiveness in global biomedical R&D as the stakes. The U.S. does lead the world in drug discovery output, measured by NDA approvals and by absolute R&D investment. PhRMA data show U.S. biopharmaceutical companies spent over $100 billion on R&D in 2022, with a significant fraction going into federally funded academic discoveries through licensing deals.
The competitiveness argument has a specific mechanism: if march-in creates sovereign IP risk for U.S.-licensed assets, international pharmaceutical companies — European, Japanese, or Chinese multinationals — lose one incentive to license American university technology rather than developing equivalent programs at domestic institutions with no Bayh-Dole strings. The aggregate effect, if significant, would reduce licensing revenues to U.S. universities and reduce the number of federally funded discoveries that reach development. This would harm the very patients that price-based march-in proponents are trying to help.
Whether this dynamic would materialize in practice is genuinely uncertain. The U.S. research base has advantages — NIH infrastructure, scientific talent concentration, FDA regulatory expertise, capital market depth — that are not easily replicated. It is unlikely that a single march-in action would prompt a wholesale reorientation of global licensing strategies. A pattern of aggressive, repeated march-in actions across multiple drugs could, over a decade, shift the calculus at the margins of licensing decisions.
Practical Compliance: What Pharma and University IP Teams Must Do Now
Bayh-Dole Compliance Obligations: The Full Checklist
The Harvard investigation brought statutory compliance obligations back into the foreground for every university and company holding patents with federal funding provenance. Bayh-Dole’s implementing regulations at 37 C.F.R. § 401 impose specific procedural requirements:
Inventors working on federally funded research must disclose new inventions to their institution in writing. The institution must disclose each new subject invention to the relevant funding agency within two years of the inventor’s written disclosure. The institution must then elect to retain title within two years of that agency disclosure, a period that can be shortened to 60 days before any public disclosure or patent bar date. All exclusive licenses on subject inventions must include the U.S. manufacturing preference clause from Section 204. Institutions must file patent applications in a timely manner and prosecute them diligently. Annual utilization reports are required for each subject invention, documenting commercialization status.
The Trump administration’s Harvard action focused on the first and third of these: timely disclosure and the U.S. manufacturing clause. For biotech and pharma companies that license university technology, the compliance burden runs upstream — they need to verify that the university licensor met its disclosure obligations correctly before the license was executed. A licensing agreement built on a Bayh-Dole noncompliant patent chain can create title defects that compromise the licensee’s own IP position.
Due Diligence Protocol for Bayh-Dole-Encumbered Assets
A practical screening protocol for Bayh-Dole exposure in pharmaceutical patent portfolios should include four components. First, identification: screen all patents in the relevant portfolio for the Statement of Federally Sponsored Research. For acquired assets, this requires reviewing the original grant records, not just the patents. The SBIR and STTR databases, NIH Research Portfolio Online Reporting Tools (RePORTER), and ClinicalTrials.gov grant disclosures are primary sources.
Second, chain of title verification: confirm that every transfer of the subject invention — from original university assignee through any spinout, licensing deal, acquisition, or merger — was executed with the government’s required licenses and approvals preserved. Bayh-Dole requires that any assignment of a federally funded patent to a new owner must include specific grant-back rights to the funding agency.
Third, price differential flagging: for products already on the market with Bayh-Dole-encumbered IP, model the U.S.-international price differential systematically. Products with a ratio greater than three-to-one compared to the median peer-nation price should be flagged as elevated march-in petition targets. This is a forward-looking risk metric, not a legal conclusion.
Fourth, advocacy monitoring: March-in petitions are public. NIH and other agencies post them when received. Systematic monitoring of petition filings against competitors’ products can provide advance intelligence on regulatory risk. A petition filed against a competitor’s drug can also signal which advocacy organizations are actively using march-in as a strategic tool, providing useful intelligence about the petitioner’s next target.
Investment Strategy: Portfolio-Level Implications
For institutional investors and portfolio managers, Bayh-Dole march-in risk has moved from unquantified background noise to a line item that belongs in drug asset valuation models. Five specific recommendations for incorporating this into investment analysis:
Price differential scoring should be calculated for every holding with Bayh-Dole provenance. Use public data sources — Medicare Part D pricing dashboards, WHO CHOICE data, IQVIA international drug price databases — to compute U.S.-international price ratios. Assets scoring above 5:1 against peer-nation medians warrant explicit scenario modeling.
Patent expiration timelines modulate march-in risk nonlinearly. As the Xtandi case shows, NIH will not invest in a procedurally slow march-in action for assets within three to four years of patent expiration. Conversely, assets with 10+ year exclusivity windows and high price differentials represent the clearest forward march-in risk.
Assess the breadth of the patent thicket protecting each at-risk product. If the federally funded patent is the composition-of-matter compound patent, march-in risk is high. If it covers only a secondary formulation or delivery mechanism, and the base compound patent is not federally funded, march-in risk is substantially reduced.
Monitor the administration’s posture toward the specific funding agency involved. NIH march-in decisions are made by the DHHS Secretary and NIH Director. DoD march-in decisions are made by the Secretary of Defense and relevant component agencies. Political alignment between an administration and a particular agency’s leadership matters for predicting action probability.
Track the financial profile of advocacy organizations filing march-in petitions. KEI has been the most consistent petitioner over the past two decades, with a track record of strategic focus on high-visibility, high-price drugs with clear federal funding provenance. Their next targets provide a leading indicator of which assets face elevated petition risk.
Key Takeaways: Compliance and Strategy
Bayh-Dole compliance is not just a university obligation — it runs to every downstream licensee and acquirer through the patent chain. The Harvard investigation set a precedent for compliance-based march-in threats independent of pricing arguments. Four-component due diligence (identification, chain of title, price differential flagging, advocacy monitoring) is now a standard-of-care expectation in pharmaceutical M&A and licensing. Investment models should quantify Bayh-Dole march-in risk as a discrete discount to NPV for assets with long exclusivity, high price differentials, and clear federal funding provenance.
The Interaction Between March-In Rights and the Inflation Reduction Act
Two Separate Instruments with Overlapping Populations
The Inflation Reduction Act (IRA) of 2022 gave Medicare authority to directly negotiate prices for high-expenditure drugs, beginning with ten drugs selected for 2026 negotiation. The selection criteria focus on Medicare Part D spend above a dollar threshold, excluding drugs with recent FDA approval (typically within the past nine years for small molecules, twelve for biologics). The first ten drugs selected for negotiation included Eliquis (apixaban), Jardiance (empagliflozin), Xarelto (rivaroxaban), Januvia (sitagliptin), Farxiga (dapagliflozin), Entresto (sacubitril/valsartan), Enbrel (etanercept), Imbruvica (ibrutinib), Stelara (ustekinumab), and Fiasp/NovoLog insulin products.
March-in rights and IRA negotiation target partially overlapping but distinct drug populations. The IRA targets aged, high-Medicare-spend drugs regardless of funding source. March-in targets federally funded patents regardless of Medicare spend, and it can theoretically apply to a drug within weeks of FDA approval if its pricing immediately generates a ‘reasonable terms’ dispute. For recently approved drugs with clear NIH or DoD funding lineage, march-in is the more proximate threat; for older high-spend drugs approaching patent expiry, IRA negotiation is the operative mechanism.
The strategic interaction between the two instruments matters. A company facing both IRA price negotiation eligibility and march-in petition risk on the same drug is in a materially weaker bargaining position than one facing either alone. An administration inclined to use march-in as leverage — credible threat without actual exercise — can use the combination to apply pressure at an early stage in a drug’s commercial life, before the IRA’s approval-age eligibility clock has run.
For drugs currently in Phase III trials with federal funding provenance and projected high list prices, modeling the combined regulatory exposure — IRA negotiation timeline, Paragraph IV challenge pipeline, and march-in petition probability — is a more complete picture of IP risk than any single metric alone.
What Comes Next: Three Scenarios for the March-In Doctrine
Scenario A: First Successful Exercise, Legal Earthquake
An agency — most likely NIH or DHHS — grants a march-in petition and issues a compulsory license to a generic manufacturer on a high-profile, high-price drug with documented NIH funding. The affected company sues in the U.S. Court of Federal Claims, which has jurisdiction to affirm, reverse, remand, or modify agency march-in decisions. The litigation goes to a circuit court and potentially to the Supreme Court on the central statutory question: does ‘available on reasonable terms’ under 35 U.S.C. § 201(f) encompass price?
This scenario produces a definitive legal answer that has eluded policymakers for 45 years, but at significant near-term cost to the innovation ecosystem. VC investment in Bayh-Dole-encumbered assets would contract during the litigation period. University TTOs would face heightened difficulty closing licensing deals while the legal status of federal IP is under adjudication.
Scenario B: Credible Threat Produces Behavioral Change Without Exercise
The NIST framework is finalized in a form that explicitly includes price as a march-in factor, agencies begin accepting petitions and initiating formal assessments, and one or two companies respond by negotiating voluntary price reductions or entering into voluntary licensing agreements rather than facing the procedural and reputational costs of a march-in proceeding. The government achieves its pricing objective through deterrence rather than action, preserving the innovation ecosystem while establishing a new pricing norm for Bayh-Dole-encumbered drugs.
This is the scenario that most closely resembles the intended design of the provision and the stated goal of recent policy moves. It requires a credible institutional commitment to march-in enforcement that no administration has yet demonstrated.
Scenario C: Congressional Intervention Resolves the Ambiguity
Congress passes legislation that explicitly amends 35 U.S.C. § 201(f) to either include or exclude price from the definition of ‘practical application.’ A law clarifying that ‘reasonable terms’ does not encompass price would codify the NIH’s long-standing position and remove the policy uncertainty that has built up over four decades. A law explicitly authorizing price-based march-in would create a new drug pricing tool with defined parameters and statutory grounding.
The current legislative environment makes this scenario low probability in the near term. The House and Senate have both passed bills addressing drug pricing through different mechanisms (IRA, reference pricing proposals, importation) without touching Bayh-Dole, suggesting that the march-in language is politically difficult to amend in a way that could attract bipartisan support.
Conclusion: The Bargain Is Being Renegotiated
The Bayh-Dole Act struck a specific bargain in 1980: private entities would receive control over taxpayer-funded IP in exchange for taking on the commercial development risk and delivering the resulting products to the public. The ‘public benefit’ requirement at the center of that bargain was understood, for four decades, to mean commercial availability, not affordability. That understanding is now contested.
The Harvard investigation in 2025 demonstrates that march-in is not solely a drug pricing issue. It is a broader instrument for enforcing the compliance obligations that are the institutional infrastructure of the Bayh-Dole bargain. The pricing debate, however intense, is one dimension of a larger question: what does the public get in return for the federal research investment that seeds most of the pharmaceutical industry’s most important advances?
The 45-year record of inaction does not mean the provision has no teeth. It means the government has, until recently, chosen not to bite. The combination of the Biden-era NIST framework, the Trump administration’s NIH affordability mandate adoption, and the Harvard compliance investigation collectively signals that the dormancy is ending — not with a single decisive action, but with a gradual ratcheting of institutional willingness to use the provision’s leverage.
For pharmaceutical executives and their investors, the correct response to this environment is not alarm and it is not dismissal. It is rigorous, systematic analysis of which assets carry Bayh-Dole exposure and in what form, followed by proactive strategy — on pricing, on patent portfolio construction, on compliance audits, and on the political-regulatory monitoring necessary to anticipate the next petition before it is filed.
Frequently Asked Questions
Does march-in transfer patent ownership to the government?
No. March-in compels the patent holder to grant a license to a designated third party — it does not transfer title. The original company retains its patents and continues to receive a royalty at the ‘reasonable’ rate determined through the march-in proceeding. The commercial damage is the loss of monopoly pricing, not the loss of the patent itself.
What is the difference between a march-in petition and a 28 U.S.C. § 1498 request?
Section 1498 is a separate statutory instrument that allows the U.S. government to use or authorize the use of a patented invention in government programs (including Medicare) without the patent holder’s consent, with compensation paid to the patent owner. It is faster to invoke than march-in because it bypasses the Bayh-Dole procedural requirements. KEI and associated advocates pursued this route for Xtandi in 2024, seeking CMS authorization for generic production for Medicare programs, in part because the march-in procedural timeline is too slow relative to Xtandi’s approaching patent expiry.
How does a drug’s IRA negotiation selection affect its march-in risk?
IRA negotiation and march-in are legally independent instruments, but they interact strategically. A drug selected for IRA negotiation has a publicly established price negotiation process underway, which may reduce the urgency of a march-in petition from an advocacy perspective. Conversely, if a company resists the IRA negotiated price and the drug has Bayh-Dole provenance, an administration could invoke march-in as additional leverage — a parallel threat that compounds negotiating pressure.
If a patent chain includes both federally and privately funded innovations, can the government march in on the entire product?
March-in attaches to the specific subject invention created with federal funds. Whether that encumbers the entire product depends on whether the federally funded patent is necessary to make, use, or sell the product. If the compound patent (the primary barrier to generic entry) is federally funded, a march-in on that patent effectively enables generic competition for the whole product. If the federally funded patent covers only a secondary feature, the practical effect of a march-in is limited.
What are the procedural steps a federal agency must follow before exercising march-in rights?
The agency must provide written notice to the contractor identifying the potential grounds for march-in and providing 30 days to respond. The contractor may then submit written and oral arguments. The agency conducts a fact-finding proceeding. If it determines march-in is warranted, it notifies the contractor in writing with the reasons. The contractor may appeal the determination, and the appeal automatically stays the march-in order during the administrative appeal process. If the appeal is denied, the order is stayed again pending judicial review. This procedural architecture is why the NIH has repeatedly cited ‘procedural inefficiency’ as a rationale for denying petitions on drugs with relatively short remaining patent lives.
Key Takeaways: Full Summary
Bayh-Dole’s march-in right under 35 U.S.C. § 203 has never been exercised by any federal agency in 45 years, but it is now being actively deployed as a threat and compliance tool by two successive administrations with entirely different policy objectives.
The ‘practical application’ trigger’s phrase ‘available on reasonable terms’ is the legal battlefield. Its meaning — whether it encompasses drug pricing — has not been authoritatively resolved by any court and has been contested in every major petition since 2004.
The Xtandi case, involving NIH/Army-funded enzalutamide co-commercialized by Astellas and Pfizer, is the definitive case study. With 2023 Medicare outlays of $2.6 billion on a single drug priced at approximately seven times its Australian equivalent, it captures every dimension of the pricing debate. Its U.S. patent expiry in 2027 and the existing generic entry pipeline have substantially reduced near-term march-in practical significance for this asset specifically.
The August 2025 Trump administration action against Harvard introduced a compliance-based march-in threat entirely distinct from pricing arguments, targeting timely invention disclosure and U.S. manufacturing obligations. This creates a second risk vector for any company whose key drug IP traces to a university that is in regulatory conflict with the federal government.
The December 2023 NIST draft framework, while not finalized, established official executive branch language connecting price to the ‘practical application’ standard. The October 2025 NIH affordability mandate adoption by the Trump administration established a durable bipartisan foothold for pricing accountability in NIH-licensed patents, irrespective of the march-in framework’s status.
For pharma IP teams, the required response is systematic Bayh-Dole chain analysis across the patent portfolio, price differential modeling for flagged assets, and proactive engagement with the regulatory monitoring infrastructure necessary to anticipate march-in petition risk before it materializes in a public petition filing. For investors, march-in risk should carry a quantified NPV discount for assets with long exclusivity, high price differentials, and clear federal funding provenance.
The dormancy of march-in rights for 45 years was not evidence of weakness — it was the product of a stable political consensus about what the Bayh-Dole bargain meant. That consensus is gone. The instrument remains exactly as powerful as it was in 1980. What has changed is the willingness to reach for it.
